Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronate Early After Hip Fracture Surgery
2020-000638-17Phase 4Active
- Sponsor
- Oslo University Hospital
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of zoledronic acid in osteoporosis and hip fracture (2 arms), sponsored by Oslo University Hospital. Primary endpoint: Bone turnover marker P1NP at 12 months. Started Jan 2021; status: active.
02
Drugs
zoledronic acid
03
Conditions
osteoporosiship fracture
Beyond the preview
Go deeper on 2020-000638-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000638-17.